• Profile

Medication adherence in patients with asthma using once-daily vs twice-daily ICS/LABAs

Journal of Asthma Oct 19, 2019

Averell CM, et al. - Researchers compared patients with asthma taking the once-daily inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) fluticasone furoate/vilanterol (FF/VI) vs the twice-daily ICS/LABAs budesonide/formoterol (B/F) and fluticasone propionate/salmeterol (FP/SAL), in terms of medication adherence and persistence in this real-world observational analysis. They used IQVIATM Health Plan Claims Data and examined patients with asthma ≥ 18 years of age starting ICS/LABA therapy with FF/VI, B/F, or FP/SAL between January 1, 2014 and June 30, 2016 (index date), in this retrospective cohort study. They matched 3,764 and 3,339 patients taking FF/VI to patients taking B/F or FP/SAL, respectively, following propensity score matching. Findings revealed better adherence and lower risk of treatment cessation in patients starting FF/VI vs B/F or FP/SAL in this real-world study, this implies possible improvement in adherence and persistence with once-daily ICS/LABA treatment vs twice-daily alternatives.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen